CA3112278A1 - Artificial tear, contact lens and drug vehicle compositions and methods of use thereof - Google Patents

Artificial tear, contact lens and drug vehicle compositions and methods of use thereof Download PDF

Info

Publication number
CA3112278A1
CA3112278A1 CA3112278A CA3112278A CA3112278A1 CA 3112278 A1 CA3112278 A1 CA 3112278A1 CA 3112278 A CA3112278 A CA 3112278A CA 3112278 A CA3112278 A CA 3112278A CA 3112278 A1 CA3112278 A1 CA 3112278A1
Authority
CA
Canada
Prior art keywords
composition
poloxamer
millimolar
polysorbate
mannitol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3112278A
Other languages
English (en)
French (fr)
Inventor
Gerald Horn
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ps Therapy Ltd
Original Assignee
Ps Therapy Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US16/137,738 external-priority patent/US20190021990A1/en
Priority claimed from US16/372,596 external-priority patent/US20190225917A1/en
Priority claimed from US16/372,582 external-priority patent/US20190224136A1/en
Priority claimed from US16/372,625 external-priority patent/US11583496B2/en
Priority claimed from US16/412,943 external-priority patent/US20190262290A1/en
Application filed by Ps Therapy Ltd filed Critical Ps Therapy Ltd
Publication of CA3112278A1 publication Critical patent/CA3112278A1/en
Pending legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/04Artificial tears; Irrigation solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/165Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/14Alkali metal chlorides; Alkaline earth metal chlorides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38Cellulose; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40Cyclodextrins; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0048Eye, e.g. artificial tears
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Ophthalmology & Optometry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA3112278A 2018-09-21 2019-09-19 Artificial tear, contact lens and drug vehicle compositions and methods of use thereof Pending CA3112278A1 (en)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US16/137,738 2018-09-21
US16/137,738 US20190021990A1 (en) 2016-10-12 2018-09-21 Artificial tear compositions and methods of use thereof
US16/372,582 2019-04-02
US16/372,596 2019-04-02
US16/372,596 US20190225917A1 (en) 2016-10-12 2019-04-02 Contact lens compositions and methods of use thereof
US16/372,582 US20190224136A1 (en) 2016-10-12 2019-04-02 Artificial tear compositions and methods of use thereof
US16/372,625 US11583496B2 (en) 2016-10-12 2019-04-02 Drug vehicle compositions and methods of use thereof
US16/372,625 2019-04-02
US16/412,943 2019-05-15
US16/412,943 US20190262290A1 (en) 2016-10-12 2019-05-15 Drug vehicle compositions and methods of use thereof
PCT/US2019/051825 WO2020061249A2 (en) 2018-09-21 2019-09-19 Artificial tear, contact lens and drug vehicle compositions and methods of use thereof

Publications (1)

Publication Number Publication Date
CA3112278A1 true CA3112278A1 (en) 2020-03-26

Family

ID=69887791

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3112278A Pending CA3112278A1 (en) 2018-09-21 2019-09-19 Artificial tear, contact lens and drug vehicle compositions and methods of use thereof

Country Status (6)

Country Link
EP (1) EP3853317A4 (https=)
JP (1) JP2022511335A (https=)
CN (1) CN113227304A (https=)
BR (1) BR112021005097A2 (https=)
CA (1) CA3112278A1 (https=)
WO (1) WO2020061249A2 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102365008B1 (ko) * 2020-06-23 2022-02-23 주식회사태준제약 디쿠아포솔을 포함하는 점안 조성물
WO2022189552A1 (en) * 2021-03-10 2022-09-15 Bausch + Lomb Ireland Limited Preservative-free contact lens treating solution
US12397518B2 (en) * 2021-04-29 2025-08-26 Coopervision International Limited WS12-releasing contact lens
CN115671256B (zh) * 2021-07-30 2024-04-09 四川大学华西医院 环孢素a与地夸磷索钠联合使用在制备治疗干眼症的药物中的用途
JP7664495B2 (ja) * 2022-10-31 2025-04-17 クーパーヴィジョン インターナショナル リミテッド Ws12-放出コンタクトレンズ
CN117338787A (zh) * 2023-11-24 2024-01-05 南京恒道医药科技股份有限公司 一种眼用药物组合物及其制备方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1321144T3 (da) * 2000-09-13 2011-03-07 Santen Pharmaceutical Co Ltd Øjendråber
US20100239518A1 (en) * 2007-09-14 2010-09-23 Yasuko Matsumura Ophthalmic composition
AU2010339993A1 (en) * 2009-12-15 2012-07-26 Foresight Biotherapeutics, Inc. Non-irritating ophthalmic povidone-iodine compositions
US8597629B1 (en) * 2013-06-21 2013-12-03 Premium Ocular Solutions LLC. Artificial tear compositions comprising a combination of nonionic surfactants
US20140377210A1 (en) * 2013-06-21 2014-12-25 Gnt, Llc Artificial tear compositions
EP3470059B1 (en) * 2015-01-26 2020-04-01 Bausch & Lomb Incorporated Ophthalmic suspension composition
JP7324566B2 (ja) * 2015-05-28 2023-08-10 ロート製薬株式会社 水性眼科組成物
WO2018071619A1 (en) * 2016-10-12 2018-04-19 Ps Therapies Ltd Artificial tear, contact lens and drug vehicle compositions and methods of use thereof

Also Published As

Publication number Publication date
EP3853317A2 (en) 2021-07-28
JP2022511335A (ja) 2022-01-31
CN113227304A (zh) 2021-08-06
EP3853317A4 (en) 2022-06-22
WO2020061249A3 (en) 2020-07-23
WO2020061249A2 (en) 2020-03-26
BR112021005097A2 (pt) 2021-06-08

Similar Documents

Publication Publication Date Title
JP7432654B2 (ja) 人工涙液、コンタクトレンズ及び薬剤担体組成物並びにその使用方法
US11583496B2 (en) Drug vehicle compositions and methods of use thereof
US11260035B2 (en) Topical compositions and methods of use thereof
CA3112278A1 (en) Artificial tear, contact lens and drug vehicle compositions and methods of use thereof
US20250367297A1 (en) Ophthalmological compositions and methods of use thereof
US20050288197A1 (en) Silicone polymer topical eye compositions and methods of use
US20190262290A1 (en) Drug vehicle compositions and methods of use thereof
US20230235247A1 (en) Contact lens compositions and methods of use thereof
US20200009044A1 (en) Artificial tear, contact lens and drug vehicle compositions and methods of use thereof
US20190225917A1 (en) Contact lens compositions and methods of use thereof
US20220133626A1 (en) Topical compositions and methods of use thereof
US20200397727A1 (en) Drug vehicle compositions and methods of use thereof
US20190021990A1 (en) Artificial tear compositions and methods of use thereof
WO2021087051A1 (en) Topical compositions and methods of use thereof
US20230285286A1 (en) Drug vehicle compositions and methods of use thereof
US20190224136A1 (en) Artificial tear compositions and methods of use thereof
BR112019007405B1 (pt) Composição de lágrima artificial
CA2567418C (en) Viscous agent for ophthalmic use
EP4652992A1 (en) Ophthalmic composition for preventing and treating conjunctiva epithelium damage and associated discomfort caused by hypotonizing formulations
JP2006089460A (ja) 眼科用粘稠化剤
HK1165274A (en) Eye-drops

Legal Events

Date Code Title Description
W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250829

U13 Renewal or maintenance fee not paid

Free format text: ST27 STATUS EVENT CODE: N-1-6-U10-U13-U300 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO MAINTENANCE FEE NOTICE

Effective date: 20251029

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260202